X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - HEALTHTECHZONE.COM - Healthcare Providers - 12/Sep 11:00

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Articles similaires

Sorry! Image not available at this time

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

healthtechzone.com - 12/Sep 11:00

Sorry! Image not available at this time

Lung Function Stable Three Years After Hematopoietic Cell Transplant in Sickle Cell

drugs.com - 05/Sep 14:09

THURSDAY, Sept. 5, 2024 -- Lung function remains stable over three years after hematopoietic cell transplant (HCT) among patients with sickle cell...

Sorry! Image not available at this time

KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024

haei.org - 06/Sep 18:54

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...

Sorry! Image not available at this time

Alive and Kicking: Watch this space on controversy-free stem-cell therapy trials, says Cynata

stockhead.com.au - 05/Sep 02:35

Stem-cell therapy Cynata Therapeutics (ASX:CYP) outlines a bulging clinical program. PTX and PEB also in the biotech news this morning. ...

Sorry! Image not available at this time

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

pharmabiz.com - 05/Sep 00:00

Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...

Sorry! Image not available at this time

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

pharmabiz.com - 05/Sep 00:00

Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...

Sorry! Image not available at this time

Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome

pharmabiz.com - 04/Sep 00:00

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Sorry! Image not available at this time

Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome

pharmabiz.com - 04/Sep 00:00

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Sorry! Image not available at this time

Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients

drugs.com - 16/Sep 14:09

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2024. Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final...

Sorry! Image not available at this time

Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma

pharmabiz.com - 14/Sep 23:19

Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...

Les derniers communiqués